moneyheap
BRKR · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Bruker Corporation (BRKR) stock moving?
Bruker's Q3 2026 report (Nov 4) beat estimates on non-GAAP EPS ($0.56 vs $0.42) and revenue ($874.0M vs $868.8M), with adjusted operating margin up about 400 bps to 16.3% and free cash flow of $96.7M versus negative a year earlier. The company reaffirmed FY2026 adjusted EPS guidance of $2.10-$2.15 but trimmed FY2026 sales guidance to $3.52B-$3.56B, and organic growth was only 0.7%. The GAAP loss reflects a $174.5M non-cash goodwill impairment. Management pointed to five straight quarters of book-to-bill above one and expects growth acceleration and double-digit EPS growth in FY27. Analysts were split: Leerink raised its target to $85 (Outperform), while Citigroup kept Neutral and raised its target to $64. The stock jumped about 13% on Nov 4 on heavy volume (7.4M shares versus roughly 2-3M on typical days), reached a 30-day intraday high of $68.98, then pulled back to $58.06 by Nov 5. It rallied to $66.54 on Nov 9 but fell 6.5% to $62.24 on Nov 10 after opening at $65.51. The stock remains well above its Nov 2 low of $55.15. Overall, the earnings beat and margin and cash flow improvement support the case, while the sales guidance cut, weak organic growth and the impairment temper it.
News behind the analysis
- TOFWERK Joins SubFAB Labs Initiative for Semiconductor Process MonitoringTOFWERK, a Bruker company, is participating in the SubFAB Labs initiative, applying its mass spectrometry technology to real-time chemical analysis in semiconductor manufacturing.
- Leerink Partners Maintains Outperform on Bruker, Raises Price Target to $85Leerink Partners kept its Outperform rating and raised its price target to $85 after the third-quarter results.
- Citigroup Maintains Neutral on Bruker, Raises Price Target to $64Citigroup kept its Neutral rating and raised its price target to $64 following the quarterly report.
- Bruker Reports Third Quarter 2026 Financial ResultsQ3-26 revenue rose 1.6% to $874.0M, with non-GAAP operating margin of 16.3% (up 400 bps) and non-GAAP EPS of $0.56 (up 24.4%); GAAP diluted loss was $(0.81) after a $174.5M goodwill impairment.
- Bruker Q3 2026 Earnings Call TranscriptManagement said Bruker Scientific Instruments has posted book-to-bill above one for five straight quarters and expects revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.
- Bruker Q3 Adj. EPS $0.56 Beats $0.42 Estimate, Sales $874.000M Beat $868.827M EstimateBruker beat both non-GAAP EPS and revenue consensus estimates for the third quarter.
- Bruker Affirms FY2026 Adj EPS Guidance of $2.10-$2.15 vs $2.12 Est; Lowers FY2026 Sales Guidance from $3.540B-$3.570B to $3.520B-$3.560B vs $3.556B EstBruker reaffirmed FY2026 adjusted EPS guidance of $2.10-$2.15 but cut its FY2026 sales guidance range to $3.52B-$3.56B.
- Bruker Q3 GAAP Results Include $174.5M Goodwill Impairment ChargeThird-quarter GAAP results include a non-cash goodwill impairment charge of $174.5M, driving the GAAP loss.
- Bruker Q3 Organic Revenue +0.7% YoY; Adj Operating Margin 16.3% vs 12.3% YoYOrganic revenue growth was only 0.7% year over year, while adjusted operating margin expanded about 400 bps.
- Bruker Q3 Free Cash Flow $96.7M vs $(54.1)M YoYFree cash flow in Q3 was $96.7M, compared with negative $54.1M a year earlier.
About Bruker Corporation
Bruker is a scientific instrument maker based in Billerica, Massachusetts. Its high-end tools include NMR spectrometers, mass spectrometers such as the timsTOF line for proteomics, X-ray and microscopy systems, and semiconductor metrology equipment. It also has a superconducting materials business, and it is a leader in many niche, high-precision categories.
How it makes money
Most of its revenue, roughly 90%, comes from the Bruker Scientific Instruments segment. That segment sells instruments, plus consumables and service, through BioSpin (NMR and preclinical imaging), CALID (mass spectrometry, microbiology and infectious-disease diagnostics), and Nano (X-ray, microscopy, spatial biology and semiconductor metrology). The Bruker Energy & Supercon Technologies (BEST) segment makes the rest by selling superconducting wire and devices. Total revenue is about $3.5 billion a year: the company's 2026 guidance is roughly $3.52–3.56 billion.
What usually moves BRKR
- Academic and government research funding, especially in the US
- Biopharma R&D and capital spending
- Semiconductor metrology orders and timing
- Cost-cutting and operating margin progress
- Currency swings and tariffs